Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin.

about

Reduced ABCB1 Expression and Activity in the Presence of Acrylic Copolymers.Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers.Enhanced oral bioavailability of fluvastatin by using nanosuspensions containing cyclodextrin

P2860

Q37712487-EA058625-4BE2-4EC4-BB80-BB0A877479F3 Q43244800-5126D4FA-0513-4F09-A7EB-05706D6D9E57 Q58698714-9662A910-BBCE-4F50-A0C7-4F5A3F6CCF63

P2860

Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin.

Item

http://www.wikidata.org/entity/Q41896286

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Effects of Fluvastatin on the ...... ein Inhibition by Fluvastatin.

@en

type

Item

label

Effects of Fluvastatin on the ...... ein Inhibition by Fluvastatin.

@en

prefLabel

Effects of Fluvastatin on the ...... ein Inhibition by Fluvastatin.

@en

P1476

Effects of Fluvastatin on the ...... ein Inhibition by Fluvastatin.

@en

P2093

Chong-Ki Lee

http://www.w3.org/2001/XMLSchema#string

Joon Seok Bang

http://www.w3.org/2001/XMLSchema#string

Jun-Shik Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue

2,3-butanediol synthesis and the emergence of the Vibrio cholerae El Tor biotype.

Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members.

Fluvastatin: a review of its use in lipid disorders.

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

Clinical pharmacokinetics of fluvastatin.

Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

Clinical pharmacokinetics and pharmacodynamics of repaglinide.

Cyclosporine markedly raises the plasma concentrations of repaglinide.

P304

245-251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4196/KJPP.2013.17.3.245

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239942328

http://www.w3.org/2001/XMLSchema#string

P698

23776402

http://www.w3.org/2001/XMLSchema#string

P932

3682086

http://www.w3.org/2001/XMLSchema#string

Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin.

about

P2860

P2860

Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932